Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

Sema Kurtuluş, Asaf Madi, Giulia Escobar, +10

Immunity

Tumor ImmunologyCancer ImmunosurveillanceImmune RegulationTumor ImmunityImmunodominance +9

TIGIT predominantly regulates the immune response via regulatory T cells

Sema Kurtuluş, Kaori Sakuishi, Shin-Foong Ngiow, +6

Journal of Clinical Investigation

T-regulatory CellImmunologyImmune RegulationImmunoeditingRegulatory T Cells +18

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

Norio Chihara, Asaf Madi, Takaaki Kondo, +18

Nature

Transcriptional RegulationSystems BiologySignal TransductionT CellsCo-inhibitory Gene Module +10

A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells

Meromit Singer, Chao Wang, Le Cong, +16

Cell

Cancer ImmunosurveillanceT-regulatory CellImmunologyTumor-infiltrating T CellsDistinct Gene Module +7

Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells

Martin Guimond, Rachelle G. Veenstra, David J. Grindler, +11

Nature Immunology

InflammationCytokineInterleukin 7Autoimmune DiseaseNiche Size +9

Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity

Karen O. Dixon, Michelle Schorer, James Nevin, +11

The Journal of Immunology

STAT5 Is Critical To Maintain Effector CD8+ T Cell Responses

Pulak Tripathi, Sema Kurtuluş, Sara Wojciechowski, +6

The Journal of Immunology

Bcl-2 Allows Effector and Memory CD8+ T Cells To Tolerate Higher Expression of Bim

Sema Kurtuluş, Pulak Tripathi, Maria E. Moreno‐Fernandez, +4

The Journal of Immunology

Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus

Tom M. McCaughtry, Ruth Etzensperger, Amala Alag, +8

The Journal of Experimental Medicine

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, +21

Blood